| |
|
|
| |
Drug Solubility Technology and Platforms
Evolving Strategies, Emerging Opportunities
|
Publication: January 2011
Product Code: DSB355F
|
Because drug molecules must be water soluble to be readily
delivered to the cellular membrane while retaining their
hydrophobic properties, issues surrounding water
insolubility of active compounds have important business and
market implications for new drug development. This impact
extends beyond potential future drug therapeutics, affecting
current reformulation strategies as well. As large-molecule
therapeutics increase in number and as a percentage of all
drug discoveries, the economic scales will tip in favor of
those drug developers possessing the ability to engineer
water-soluble formulations of inherently hydrophobic
compounds. The importance of solubilization technologies is
also underscored by the capability they bestow on
formulators attempting to re-formulate approved drugs
approaching the end of their patent life. The survey covers
a dozen solubilization technologies and processes, including
particle engineering, supercritical fluid processing,
liposomes, modified sugars and starches, nanoparticles, and
micelle structures. |
|
Highlights |
· Analyzes and evaluates
drug formulation processes and technologies for
improving the properties of insoluble poorly soluble
and/or poorly absorbed drug candidates
· Examines drug
formulation issues and
evolving market factors
· Provides detailed
assessments and status of commercial drug formulation
technology platforms designed to improve drug solubility
· Profiles drug solubility
technology market participants, their research
activity, proprietary technology, and business
strategies
|
|
Summary of Contents |
Executive Summary
Drug Formulation Market
Dynamics
Trends in Formulation Science
Drug Discovery Automation
Drug Development
Productivity
Preclinical Development Issues
Value-added Contract Formulators
Technology
Market Drivers
Formulation Strategies
Drug Formulation Technology Factors
Drug
Candidate Characterization
Active Compound
Stability
Physicochemical Properties
Drug
Solubility
Routes of Administration
Drug
Solubility Technology
Cyclodextrins
Liposomes
Micelles
Microgels
Nanosystems
Particle Engineering
Supercritical Fluid
Processing
Polyethylene Glycol
Porous
Microparticles
Salt Formation
Starch
Derivatives
Drug Solubility Testing
Standards and Testing Criteria
Testing
Technology
Compound Screening
Drug
Solubility Test Systems
Selected Solubility
Testing Provider Profiles
Drug Solubility
Technology Platform Assessments
Biorise (Eurand)
Biotransport (SupraTek Pharma)
Captisol (CyDex)
Chitosan (Archimedes)
Cyclosert (Calando)
Diffucaps (Eurand)
EPAS (PharmaForm)
EUDRAGIT (Evonik)
FluidCrystals (Camurus)
Formulplex (Supercritical Solutions)
HySolv (Novartis)
IDD (SkyePharma)
Labrafil/Gelucire (Gattefosse)
Lip’ral (Lipocine)
Medusa (Flamel Technologies)
MeltDose
(Lifecycle Pharma)
Melt Spray-Congealed
Microspheres (Bend Research)
Nanocrystals (Elan)
NanoMorph (Soliqs)
NovaSOL ( Aquanova)
Novasperse (PharmaNova)
OctoDex (OctoPlus)
PNDS (Labopharm)
ProRelease (Synectix)
PVA-co-PEG (Formac)
RubiEn (Rubicon Research)
Solumer (SoluBest)
Soluplus (BASF)
Market Factors
FDA Regulations
Clinical Trials
Formulation Partnerships
Protein and Peptide-based Drugs
Dosage Forms
Drug Delivery Technology
Company Profiles
|
|
|
|
|
